Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing Lp(a) levels. Mipomersen, an antisense oligonucleotide that inhibits apoB synthesis, is approved for the treatment of homozygous familial hyp...

Full description

Bibliographic Details
Main Authors:	Renu Nandakumar, Anastasiya Matveyenko, Tiffany Thomas, Marianna Pavlyha, Colleen Ngai, Stephen Holleran, Rajasekhar Ramakrishnan, Henry N. Ginsberg, Wahida Karmally, Santica M. Marcovina, Gissette Reyes-Soffer
Format:	Article
Language:	English
Published:	Elsevier 2018-12-01
Series:	Journal of Lipid Research
Subjects:	fractional clearance rate production rate apoB antisense treatment
Online Access:	http://www.sciencedirect.com/science/article/pii/S002222752034164X

Internet

http://www.sciencedirect.com/science/article/pii/S002222752034164X

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Internet

Similar Items